Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
9 hedge funds and large institutions have $130K invested in Sonnet BioTherapeutics in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
4,287% more capital invested
Capital invested by funds: $2.97K → $130K (+$127K)
350% more funds holding
Funds holding: 2 → 9 (+7)
2.95% more ownership
Funds ownership: 0.01% → 2.96% (+3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$138K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$83.8K |
| 3 |
Two Sigma Investments
New York
|
+$67K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$20K |
| 5 |
CWA
Carolina Wealth Advisors
Myrtle Beach,
South Carolina
|
+$112 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
1
Virtu Financial
New York
| $58K | +$138K | +39,647 | New |
|
|
2
Citadel Advisors
Miami,
Florida
| $35.1K | +$83.8K | +24,013 | New |
|
|
3
Two Sigma Investments
New York
| $28K | +$67K | +19,203 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $8.91K | +$20K | +5,722 | +1,514% |
|
5
BlackRock
New York
| $95 | – | – | – |
|
|
CWA
6
Carolina Wealth Advisors
Myrtle Beach,
South Carolina
| $47 | +$112 | +32 | New |
|
7
Bank of America
Charlotte,
North Carolina
| $7 | +$17 | +5 | New |
|
8
UBS Group
Zurich,
Switzerland
| $4 | +$10 | +3 | New |
|
9
Citigroup
New York
| $3 | +$7 | +2 | New |
|
SONN Hedge Fund Activity: Q4 2024 in Review
9 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q4 2024, worth a combined $130K — up 4,287% from $2.97K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new SONN positions and 0 closed out — a net gain of 7 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $138K.
- 9 institutional investors held Sonnet BioTherapeutics (SONN) as of Q4 2024, up from 2 in Q3 2024.
- Funds reported $130K of Sonnet BioTherapeutics stock for Q4 2024, up 4,287% quarter-over-quarter.
- 7 funds opened new Sonnet BioTherapeutics positions in Q4 2024 and 0 closed out, a net change of +7 holders.
- The largest Sonnet BioTherapeutics buyer in Q4 2024 was Virtu Financial, an estimated $138K added.
Based on aggregated 13F filings for Q4 2024.